这条明星信号通路已催生多款重磅新药 治疗多种炎症性疾病(3)
2019-05-12 未知 admin
参考资料:
[1] Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200. Retrieved April 22, 2019, from https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-completion-of-phase-1-clinical-trial-of-oral-il-23-receptor-antagonist-ptg-200-300743279.html
[2] FDA Approves Tildrakizumab for Certain Plaque Psoriasis Patients. Retrieved April 22, 2019, from https://www.mdmag.com/medical-news/fda-approves-tildrakizumab-for-certain-plaque-psoriasis-patients
[3] Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study. Retrieved April 22, 2019, from https://www.prnewswire.com/news-releases/bimekizumab-demonstrated-long-term-maintenance-of-complete-or-almost-complete-skin-disease-resolution-for-psoriasis-patients-in-be-able-2-extension-study-300805419.html
[4] Valeant Announces U.S. Launch of SILIQ? (brodalumab) Injection. Retrieved April 22, 2019, from https://ir.bauschhealth.com/news-releases/2017/07-27-2017-120303730
[5] SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 1/22/19, Retrieved April 22, 2019, from https://jnj-content-lab.brightspotcdn.com/cd/89/89043e9145439087cd8986134485/jnj-pipeline-4q2018.pdf
[6] Risankizumab. Retrieved April 22, 2019, from https://www.abbvie.com/our-science/pipeline/risankizumab.html
[7] Key programs in development that derive from our Open Science pipeline. Retrieved April 22, 2019, from https://www.allergan.com/research-and-development/areas-of-focus/advancing-the-pipeline
[8] MEDICINES IN DEVELOPMENT. Retrieved April 22, 2019, from https://www.lilly.com/discovery/pipeline
[9] Moschen et al. (2018). IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nature Reviews Gastroenterology & Hepatology, https://doi.org/10.1038/s41575-018-0084-8
[10] Biachi and Rogge (2019). The IL-23/IL-17 pathway in human chronic inflammatory diseases—
new insight from genetics and targeted therapies. Genes & Immunity, https://doi.org/10.1038/s41435-019-0067-y
[11] Boutet et al. (2019). Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19020530
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。鐑瘝锛